Patents by Inventor José William Saldanha

José William Saldanha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to VLA-1
    Patent number: 7910099
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: March 22, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Antibodies to VLA-1
    Publication number: 20100272716
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 28, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Antibodies to VLA-1
    Patent number: 7723073
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: May 25, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Humanized antibodies that recognize ?-amyloid peptide
    Patent number: 7700751
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: April 20, 2010
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7582733
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: September 1, 2009
    Assignees: Elan Pharma International Limited, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha
  • ANTIBODY AND ANTIBODY FRAGMENTS FOR INHIBITING THE GROWTH OF TUMORS
    Publication number: 20090099339
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: July 9, 2008
    Publication date: April 16, 2009
    Applicant: ImClone Systems Incorporated
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • HUMANIZED ANTI-LT-beta-R ANTIBODIES
    Publication number: 20090092601
    Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.
    Type: Application
    Filed: June 30, 2008
    Publication date: April 9, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE
    Publication number: 20090069544
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Application
    Filed: August 20, 2007
    Publication date: March 12, 2009
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Reshaped human antibody to human interleukin-6 receptor
    Patent number: 7479543
    Abstract: A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: January 20, 2009
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masayuki Tsuchiya, Koh Sato, Mary Margaret Bendig, Steven Tarran Jones, Jose William Saldanha
  • ANTIBODIES TO VLA-1
    Publication number: 20090010930
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: January 16, 2008
    Publication date: January 8, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE
    Publication number: 20080281082
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Application
    Filed: August 20, 2007
    Publication date: November 13, 2008
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Humanized anti-LT-?-R antibodies
    Patent number: 7429644
    Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: September 30, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • Humanized anti-lymphotoxin beta receptor antibodies
    Patent number: 7429645
    Abstract: This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-?-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: September 30, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Kenneth Simon, Jose William Saldanha
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7189819
    Abstract: The invention provides improves agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 13, 2007
    Assignees: Wyeth, Neuralab Limited
    Inventors: Guriq Basi, Jose William Saldanha
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7179892
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: February 20, 2007
    Assignees: Neuralab Limited, Wyeth
    Inventors: Guriq Basi, Jose William Saldanha
  • Humanized anti-EGF receptor monoclonal antibody
    Patent number: 7060808
    Abstract: A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: June 13, 2006
    Assignee: ImClone Systems Incorporated
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Humanized anti-LT-beta-R antibodies
    Publication number: 20040058394
    Abstract: Humanized antibodies to LT-&bgr;-R and methods of use thereof are provided.
    Type: Application
    Filed: April 10, 2003
    Publication date: March 25, 2004
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • Antibody and antibody fragments for inhibiting the growth of tumors
    Publication number: 20040006212
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: February 25, 2003
    Publication date: January 8, 2004
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • Antibody and antibody fragments for inhibiting the growth of tumors
    Publication number: 20030224001
    Abstract: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
    Type: Application
    Filed: February 25, 2003
    Publication date: December 4, 2003
    Inventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha
  • FAPalpha -specific antibody with improved producibility
    Publication number: 20030143229
    Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.
    Type: Application
    Filed: June 3, 2002
    Publication date: July 31, 2003
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Leger, Jose William Saldanha